Charles River Laboratories International (CRL) Aandeel Koers

Charles River Laboratories International Inc is primarily active in the life sciences industry.

Some of the main competitors of Charles River Laboratories International Inc in the market include Covance Inc., Envigo, PPD, Eurofins Scientific, and LabCorp.

Charles River Laboratories International Inc is a renowned company in the field of preclinical and clinical laboratory services. Founded in 1947, Charles River has built a strong reputation as a trusted provider of comprehensive research support. With a focus on helping pharmaceutical and biotechnology companies bring new drugs to market, they offer a wide range of services including drug discovery, safety assessment, and manufacturing support to clients worldwide. The company's expertise in advanced animal models, laboratory sciences, and support services has propelled it to the forefront of the life sciences industry. Today, Charles River Laboratories continues to play a vital role in advancing much-needed medical therapies.

Charles River Laboratories International Inc has achieved several significant milestones. It has consistently demonstrated strong financial performance, delivering consistent revenue growth and expanding its global footprint. The company has successfully completed strategic acquisitions, enabling it to enhance its capabilities and expand its service offerings. Charles River Laboratories International Inc has also received notable recognition, including being named one of the World's Most Ethical Companies for several consecutive years. Moreover, the company has been at the forefront of scientific advancements, collaborating with global pharmaceutical and biotechnology companies to develop innovative solutions that improve drug discovery and development processes.

Charles River Laboratories International Inc is primarily present in the following countries and regions: United States, Canada, Europe, Asia Pacific, and Latin America.

Charles River Laboratories International Inc represents various values and corporate philosophies. The company is committed to their mission of improving the lives of people and animals through innovative research and development. They aim to maintain the highest standards of scientific integrity, ethical conduct, and regulatory compliance. Charles River Laboratories prioritizes collaboration and partnership with their clients to provide comprehensive solutions and exceptional service. With a focus on quality, efficiency, and expertise, they strive to consistently deliver reliable and innovative scientific services and products. Through their dedication to responsible and sustainable practices, Charles River Laboratories aims to make a positive impact on society and the environment.

Analisten hanteren momenteel een gemiddeld koersdoel van 267,60 USD voor het aandeel Charles River Laboratories International (mediaan: 273,00 USD), oftewel -10,7 % ten opzichte van de laatste koers. De consensus is gebaseerd op 23 analistenratings.

Charles River Laboratories International Koersdoelstellingen analisten 2026

23 analisten beoordelen het aandeel Charles River Laboratories International momenteel: 17 adviseren kopen, 6 houden en 0 verkopen. Voor 2026 verwachten analisten dat Charles River Laboratories International een omzet van 3,91 Miljard USD en winst per aandeel van 11,44 USD behaalt.

Charles River Laboratories International Koersdoelstellingen analisten 2026

Omgezet tegen de huidige wisselkoers noteert het aandeel Charles River Laboratories International op 267,37 EUR (299,66 USD).

Het aandeel Charles River Laboratories International (CRL) is genoteerd aan 6 beurzen, waaronder: NYSE (CRL), SIX (Zürich) (RV6.SW), XETRA (RV6.DE), Frankfurt (RV6.F), München (RV6.MU), Düsseldorf (RV6.DU).

Charles River Laboratories International Inc is a global leader in the field of life sciences, offering its customers a wide range of products and services. The company's business model is based on three main areas: research and development, preclinical services, and bioproducts. Research and Development: Charles River Laboratories offers a variety of services to support its customers in the development of new products. These include chemical and pharmacological screening systems, study design and planning, cell and tissue banking, genotoxicology, protein and antibody production, and much more. Charles River Laboratories has a comprehensive range of scientific and technical capabilities to assist its customers in the development of new drugs, biotechnology products, and medical devices. Preclinical Services: The company provides its customers with a wide range of preclinical services to test the safety and efficacy of products. These services include toxicology, pathology, pharmacology, bioanalytics, and clinical diagnostics. Charles River Laboratories has several preclinical research facilities worldwide and can support customers in the validation of new therapies and products. Bioproducts: Charles River Laboratories produces a variety of bioproducts for research and development, including cell lines, antibodies, nucleic acids, and proteins. The company also offers specialized services such as genetic manipulation and custom modification of cell lines to achieve specific research goals. The company focuses on customer loyalty and has earned the trust of customers by offering high-quality products and services. Charles River Laboratories has a global presence with facilities in North America, Europe, and Asia, and can serve customers worldwide. The company also maintains a strong partnership with the scientific community by supporting research initiatives and public health measures. Charles River Laboratories is committed to offering its customers a comprehensive range of services to meet their needs in the field of life sciences. The company is dedicated to continuously improving its research and development and introducing new services and products to meet the ever-changing needs of customers.

De verwachte omzet van Charles River Laboratories International bedraagt 3,91 Miljard USD. Deze cijfers zijn gebaseerd op huidige financiële gegevens en weerspiegelen de bedrijfsresultaten van het bedrijf.

De verwachte winst van Charles River Laboratories International bedraagt 563,17 Miljoen USD. De nettowinst weerspiegelt de rentabiliteit van het bedrijf na aftrek van alle kosten.

De koers-winstverhouding (P/E) van Charles River Laboratories International bedraagt momenteel 26,19. De P/E-ratio vergelijkt de huidige aandeelkoers met de winst per aandeel en helpt beleggers de waardering van het Charles River Laboratories International-aandeel in te schatten.

De koers-omzetverhouding (P/S) van Charles River Laboratories International bedraagt momenteel 3,77. De P/S-ratio vergelijkt de marktkapitalisatie met de jaarlijkse opbrengsten en dient als waarderingsmaatstaf voor het Charles River Laboratories International-aandeel.

De Eulerpool Kwaliteitsscore voor Charles River Laboratories International is 3/10.

De ISIN van Charles River Laboratories International is US1598641074. De ISIN (International Securities Identification Number) is een wereldwijd unieke identificatie voor wertpapieren.

De WKN van Charles River Laboratories International is 939391. De WKN (Wertpapierkennnummer) is een zescijferig Duits identificatienummer voor wertpapieren.

Het tickersymbool van Charles River Laboratories International is CRL. Onder dit beurstickersymbool wordt het Charles River Laboratories International-aandeel op de beurs verhandeld.